Press Releases | Insilico Medicine

Press Releases

2023

Insilico announces the expansion of its oncology pipelines and delivers the new generation FGFR2/3 inhibitor

28 December 2023

Insilico announces the second generation DGKA inhibitor for the treatment of PD-1/PD-L1 resistance solid tumors

26 December 2023

Insilico Medicine leadership to attend 42nd Annual J.P. Morgan Healthcare Conference

18 December 2023

Insilico Medicine announces AI drug discovery milestone achievement in pharma collaboration

12 December 2023

In 7 months, online Target ID course from AI drug discovery company Insilico Medicine surpasses 2,500 users

11 December 2023

Insilico Medicine announces first-in-human study for oral PHD 1/2 inhibitor ISM5411 for inflammatory bowel disease (IBD)

7 December 2023

Insilico Medicine showcases latest AI drug discovery platform breakthroughs

29 November 2023

International team uses AI platform to find dual targets for aging and cancer

16 November 2023

Insilico Medicine presents at Future Investment Initiative Conference in Riyadh

20 October 2023

Insilico Medicine nominates novel CDK12/13 small molecule inhibitor as preclinical candidate for multiple tumors

17 October 2023

Insilico Medicine presents data on AI-designed cancer drugs at 3 major cancer conferences

16 October 2023

Insilico Medicine founder and CEO Alex Zhavoronkov, Ph.D., to present on AI drug discovery at LSX Nordic Congress

5 October 2023

Insilico Medicine discovers novel dual targets for aging and disease using Microsoft BioGPT

27 September 2023

Insilico Medicine and University of Cambridge present new approach to discover targets for Alzheimer's and other diseases with protein phase separation

25 September 2023

Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor

12 September 2023

Global Entanglement: Insilico Medicine presents at Morgan Stanley Global Healthcare Conferences in the U.S. and Asia

5 September 2023

World's largest aging research and drug discovery conference celebrates 10 years

23 August 2023

Insilico advances anti-tumor drug to Phase I, marking first clinical milestone in Fosun Pharma collaboration

15 August 2023

Insilico Medicine joins Montreal Chamber of Commerce to drive continued innovation

8 August 2023

After 7 years, generative AI succeeds in predicting clinical trial outcomes

3 August 2023

Insilico Medicine leverages generative AI and AlphaFold structures for novel cancer drug

2 August 2023

AI drives new era of target identification and drug design

1 August 2023

Michael Bayewitch, PhD named Head of BD and Licensing North America for Insilico Medicine

28 July 2023

Insilico Medicine nominates preclinical candidate of inhalation solution for ISM001-055, the first generative AI IPF drug

20 July 2023

Insilico Medicine scientists propose stricter standards for evaluating generative AI-produced molecules

18 July 2023

Scientists use Insilico Medicine's generative AI platform to predict drug targets for rare lysosomal storage disease

14 July 2023

Emerging tech storyteller Taryn Southern announced as Docuthon judge

11 July 2023

Insilico Medicine appoints Sujata Rao, MD as Chief Medical Officer

29 June 2023

First drug discovered and designed with generative AI enters Phase II trials, with first patients dosed

27 June 2023

Insilico Medicine's transformer-based aging clock provides insights into aging, disease, and new therapeutic targets

15 June 2023

Insilico Medicine announces potential best-in-class pan-TEAD inhibitor candidate ISM6331 targeting advanced solid tumors

8 June 2023

Insilico Medicine Founder and CEO Alex Zhavoronkov, PhD presents at Jefferies Global Healthcare Conference

7 June 2023

Insilico Medicine receives IND approval for novel AI-designed USP1 inhibitor for cancer

25 MAY 2023

Insilico Medicine founder and CEO Alex Zhavoronkov, Ph.D., presents on AI Drug Discovery for NIH National Institute on Drug Abuse

23 MAY 2023

Insilico Medicine-led study combines quantum computing and generative AI for drug discovery

19 MAY 2023

Insilico Medicine delivers preclinical candidate targeting ENPP1 for cancer immunotherapy and the treatment of rare disease using generative AI

18 MAY 2023

Insilico Medicine founder and CEO Alex Zhavoronkov, PhD, presents at Asia Summit on Global Health

16 MAY 2023

Insilico Medicine appoints Michael Bayewitch as VP, Business Development and Strategy

15 MAY 2023

Insilico Medicine founder and CEO to give keynote on disease modeling with AI at PEGS Boston

11 MAY 2023

AI drug discovery company Insilico Medicine offers free course on target identification

10 MAY 2023

Head of Insilico Medicine's Hong Kong Office to give keynote on AI drug discovery at HKUST Big Data Institute

4 MAY 2023

High school student researchers find new brain tumor drug targets using AI

2 MAY 2023

Insilico Medicine founder and CEO Alex Zhavoronkov, Ph.D., presents at LSX World Congress

28 APRIL 2023

Insilico Medicine successfully discovered potent, selective, and orally bioavailable small-molecule inhibitor of CDK8 using generative AI

12 APRIL 2023

Insilico Medicine presents four posters featuring AI-designed anti-cancer drugs at AACR

4 APRIL 2023

Using AI to address aging and disease: Insilico Medicine's Alex Zhavoronkov, PhD presents at the Geroscience Summit

3 APRIL 2023

Insilico Medicine featured in BBC-produced series on biotech breakthroughs

29 MARCH 2023

Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform

13 MARCH 2023

Generative AI for drug discovery expert Alex Zhavoronkov, Ph.D. presents at NextMed Health March 14

10 MARCH 2023

Insilico Medicine's Generative AI Pioneer Alex Zhavoronkov, PhD at Lab of the Future March 9

1 MARCH 2023

Insilico Medicine sends first generative AI-designed drug for COVID-19 and variants to clinic

23-FEBRUARY-2023

Tech journalist and filmmaker Amelia Martyn-Hemphill announced as Docuthon judge

21-FEBRUARY-2023

Emmy Award-winning filmmaker Oren Rosenfeld joins Insilico Medicine's Docuthon as judge

9-FEBRUARY-2023

Insilico Medicine receives FDA Orphan Drug Designation for generative AI discovered and designed drug for idiopathic pulmonary fibrosis

8-FEBRUARY-2023

New paper explores Insilico Medicine's generative AI drug design platform Chemistry42

7-FEBRUARY-2023

Insilico Medicine opens largest AI-powered biotechnology research center in the Middle East

1-FEBRUARY-2023

New study uses AlphaFold and AI to accelerate design of novel drug for liver cancer

19-JANUARY-2023

Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target

10-JANUARY-2023

2022

Insilico Medicine nominates potential first-in-class preclinical candidate with novel AI-designed structure for novel AI-discovered target in immuno-oncology

20-DECEMBER-2022

Read

Insilico Medicine Awarded Over $700,000 to Design New Contraceptive Options with AI

16-NOVEMBER-2022

Read

Insilico Medicine receives Company of the Year Award at BioCentury-BayHelix East-West Summit

16-NOVEMBER-2022

Read

Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion

8-NOVEMBER-2022

Read

Deepfake Technology in Drug Design. Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event

20-OCTOBER-2022

Read

Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities

10-SEPTEMBER-2022

Read

Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million

10-AUGUST-2022

Read

Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine

07-JULY-2022

Read

Insilico Medicine appoints Dr. Feng Ren as co-CEO

16-JUNE-2022

Read

Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Automated Laboratory

06-JUNE-2022

Read

Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment

24-MAY-2022

Read

CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World

17-MAY-2022

Read

Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers

05-MAY-2022

Read

Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders

13-APR-2022

Read

Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform

25-JAN-2022

Read

Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets

11-JAN-2022

Read

Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference

06-JAN-2022

Read

Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation

05-JAN-2022

Read

Track the news on

Be the first to know our news!

Once a month you will learn about our latest features and hottest news.
And no spam of course.

By clicking the button you agree to our Privacy Policy